Early insulin combined with metformin therapy and long-term risks of cardiovascular disease, kidney disease, and cancer in newly diagnosed type 2 diabetes: a real-world cohort study in China.

Authors

Luning Yan, Qingxin Luo, Juying Wang, Shuo Zhang, Ruize Xu, Mingyue Lv, Ping Su, Shuaijie Zhang, Xiaokang Ji, Gaopei Zhu, Fuzhong Xue

Published in

Frontiers in endocrinology. Volume 17. Pages 1877839. Epub Sep 21, 2026.

Abstract

To evaluate the longitudinal associations of early insulin combined with metformin therapy, compared with metformin monotherapy, with subsequent risks of stroke, heart failure, chronic kidney disease, and cancer among adults with newly diagnosed type 2 diabetes using real-world data.
We conducted an active-comparator new-user cohort study using the Cheeloo LEAD electronic health record database (Shandong, China; 2014-2021). Adults aged 40-85 years who initiated early insulin combined with metformin therapy or metformin monotherapy during 2014-2017 were included in the common parent cohort (n=19,908; 4,304 [21.6%] and 15,604 [78.4%], respectively). Follow-up began at each treatment strategy initiation date (t0). Four independent outcome-specific subcohorts excluded patients with the corresponding pre-existing outcome and those with the outcome recorded within 30 days after t0. The combination group required at least 14 days of overlapping insulin and metformin use. L1-regularized propensity score matching and Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) over up to 1,500 days. Sensitivity analyses used a 180-day outcome-exclusion window.
Compared with metformin monotherapy, early insulin combined with metformin therapy was associated with a lower hazard of stroke (HR 0.88, 95% CI 0.78-0.99) and higher hazards of heart failure (HR 1.18, 95% CI 1.02-1.36), chronic kidney disease (HR 1.37, 95% CI 1.03-1.83), and cancer (HR 1.37, 95% CI 1.14-1.66). Exploratory subgroup estimates varied by age and sex; no formal interaction tests were performed. Results were broadly consistent in sensitivity analyses.
Early insulin combined with metformin therapy and metformin monotherapy showed different longitudinal associations with the four outcomes. These findings should be interpreted in light of residual confounding by baseline disease severity and treatment indication and may inform risk monitoring in routine care.

PMID:
42835393
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.